At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs.
Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding Intermediates Targeting) leverages the enabling breakthrough of performing atomistic protein folding pathways simulations to unveil a new class of folding interfering degraders.
Sibylla...
At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs.
Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding Intermediates Targeting) leverages the enabling breakthrough of performing atomistic protein folding pathways simulations to unveil a new class of folding interfering degraders.
Sibylla’s drugs are small-molecule protein degraders, and PPI-FIT applies to any therapeutic area.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.